Talk:GLP-1 receptor agonist

Requested move 5 November 2023

 * The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: Moved (closed by non-admin page mover) BegbertBiggs (talk) 15:15, 12 November 2023 (UTC)

Glucagon-like peptide-1 receptor agonist → GLP-1 receptor agonist – The majority of scholarly sources don't seem to be spelling out the name, per Google Scholar results since 2019: Thus, I think it meets WP:ACROTITLE for using an acronym in the title, and I also think that GLP-1 is more recognizable to our readership than the spelled out name. I would also support "GLP-1 agonist" if that's what the consensus goes for, as this term is used in many sources aimed at a popular audience (see Google search or news results). (t &#183; c)  buidhe  04:30, 5 November 2023 (UTC)
 * GLP-1 agonist: 4,000
 * GLP-1 receptor agonist: 10,600
 * "Glucagon-like peptide-1 receptor agonist" 9700
 * "Glucagon-like peptide-1 agonist": 900


 * Support - following ACROTITLE . But just a comment that related pages are not moved yet. See Glucagon-like peptide-1 and Glucagon-like peptide-1 receptor Hongsy (talk) 02:41, 9 November 2023 (UTC)
 * It's not necessarily the case that they need or should be the same, after all we have Central Intelligence Agency but CIA controversies. I think the other articles need evaluating on their own merits especially since they are of more scientific /less popular interest than this article. (t &#183; c)  buidhe  02:52, 9 November 2023 (UTC)